Not Tagged
Not Tagged
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
dynamic crc study (n&gt;450, 2:1 rct): ctdna-guided adj therapy vs vs standard adj care (soc): adj chemo: 15% vs 28% (oxali: 62% vs 10%) no diff in 2yr rfs for ctdna-guided vs soc t3 low recurrence risk. t4 could they still benefit from adj chemo? #asco22 
Translational Medical Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data) @OncoAlert. Motto: "Let's make a difference". Views mine.